const crypto = require('crypto');

class ZortexEngine {
  constructor() {
    this.geneTherapyProtocols = [
      {
        gene: 'PCSK9',
        target: 'LDL Cholesterol reduction',
        method: 'CRISPR-Cas9 base editing',
        efficacy: 0.89,
        riskLevel: 'moderate',
        fdaStatus: 'Phase 2 clinical trial',
        description: 'Knockout of PCSK9 gene reduces LDL by up to 60% permanently'
      },
      {
        gene: 'TERT',
        target: 'Telomere extension',
        method: 'AAV-mediated gene delivery',
        efficacy: 0.75,
        riskLevel: 'experimental',
        fdaStatus: 'Pre-clinical',
        description: 'Activation of telomerase reverse transcriptase extends cellular lifespan'
      },
      {
        gene: 'MYOSTATIN',
        target: 'Muscle hypertrophy',
        method: 'CRISPR-Cas9 knockout',
        efficacy: 0.92,
        riskLevel: 'moderate',
        fdaStatus: 'Phase 1 clinical trial',
        description: 'Myostatin inhibition leads to 40% muscle mass increase'
      },
      {
        gene: 'SIRT6',
        target: 'DNA repair enhancement',
        method: 'AAV9 delivery of SIRT6',
        efficacy: 0.81,
        riskLevel: 'experimental',
        fdaStatus: 'Pre-clinical',
        description: 'Overexpression of SIRT6 improves DNA repair and extends lifespan 15-30%'
      },
      {
        gene: 'KLOTHO',
        target: 'Anti-aging protein production',
        method: 'AAV-mediated overexpression',
        efficacy: 0.84,
        riskLevel: 'experimental',
        fdaStatus: 'Pre-clinical',
        description: 'Klotho protein overexpression reverses age-related cognitive decline'
      },
      {
        gene: 'FOXP3',
        target: 'Autoimmune regulation',
        method: 'CAR-T regulatory cell therapy',
        efficacy: 0.78,
        riskLevel: 'moderate',
        fdaStatus: 'Phase 2 clinical trial',
        description: 'Engineered Tregs suppress autoimmune responses in MS, Type 1 diabetes'
      },
      {
        gene: 'HBB',
        target: 'Sickle cell disease cure',
        method: 'CRISPR-Cas9 gene correction',
        efficacy: 0.94,
        riskLevel: 'FDA-approved',
        fdaStatus: 'Approved (Casgevy)',
        description: 'FDA-approved gene therapy for sickle cell disease'
      },
      {
        gene: 'CFTR',
        target: 'Cystic fibrosis',
        method: 'Base editing correction',
        efficacy: 0.86,
        riskLevel: 'moderate',
        fdaStatus: 'Phase 1 clinical trial',
        description: 'Correction of CFTR mutations restores chloride channel function'
      }
    ];
    
    this.epigeneticMarkers = [
      { marker: 'DNAmAge', normal: '< chronological age', optimal: '< chronological age - 5', method: 'Horvath clock' },
      { marker: 'GrimAge', normal: '< chronological age', optimal: '< chronological age - 7', method: 'GrimAge v2' },
      { marker: 'DunedinPACE', normal: '< 1.0', optimal: '< 0.85', method: 'DunedinPACE' },
      { marker: 'PhenoAge', normal: '< chronological age', optimal: '< chronological age - 3', method: 'PhenoAge' }
    ];
  }

  async analyzeGeneticRisk(genotypeData) {
    console.log('🧬 ZORTEX: Analyzing genetic risk profile...');
    
    const risks = [];
    const recommendations = [];
    
    // APOE analysis (Alzheimer's risk)
    if (genotypeData.apoe) {
      const apoeRisk = this.analyzeAPOE(genotypeData.apoe);
      risks.push(apoeRisk);
      if (apoeRisk.risk > 0.5) {
        recommendations.push({
          gene: 'APOE',
          intervention: 'Increase omega-3 intake (2g EPA+DHA daily), regular aerobic exercise, cognitive training',
          urgency: 'high',
          rationale: 'APOE4 carriers have 3-15x Alzheimer\'s risk'
        });
      }
    }
    
    // MTHFR analysis
    if (genotypeData.mthfr) {
      const mthfrRisk = this.analyzeMTHFR(genotypeData.mthfr);
      risks.push(mthfrRisk);
      if (mthfrRisk.risk > 0.3) {
        recommendations.push({
          gene: 'MTHFR',
          intervention: 'Switch to methylfolate (5-MTHF) instead of folic acid, increase B12 as methylcobalamin',
          urgency: 'moderate',
          rationale: 'MTHFR variants reduce folate metabolism by 30-70%'
        });
      }
    }
    
    // BRCA analysis
    if (genotypeData.brca) {
      risks.push({
        gene: 'BRCA1/2',
        risk: genotypeData.brca === 'pathogenic' ? 0.85 : 0.15,
        condition: 'Hereditary breast/ovarian cancer',
        recommendation: 'Enhanced screening, consider prophylactic options with genetic counselor'
      });
    }
    
    // Match gene therapy protocols
    const applicableTherapies = this.geneTherapyProtocols.filter(p => 
      genotypeData.conditions && genotypeData.conditions.some(c => 
        p.target.toLowerCase().includes(c.toLowerCase())
      )
    );
    
    return {
      geneticRisks: risks,
      recommendations: recommendations,
      applicableGeneTherapies: applicableTherapies,
      epigeneticTargets: this.epigeneticMarkers,
      analysisId: crypto.randomUUID(),
      timestamp: new Date().toISOString(),
      disclaimer: 'Educational analysis only. Genetic counseling required for clinical decisions.'
    };
  }
  
  analyzeAPOE(variant) {
    const riskMap = {
      'e2/e2': { risk: 0.05, description: 'Reduced Alzheimer\'s risk' },
      'e2/e3': { risk: 0.10, description: 'Low risk' },
      'e3/e3': { risk: 0.15, description: 'Average risk' },
      'e3/e4': { risk: 0.35, description: 'Moderate risk (2-3x)' },
      'e4/e4': { risk: 0.75, description: 'High risk (10-15x)' }
    };
    const result = riskMap[variant] || { risk: 0.15, description: 'Unknown variant' };
    return {
      gene: 'APOE',
      variant: variant,
      risk: result.risk,
      condition: 'Alzheimer\'s Disease',
      description: result.description
    };
  }
  
  analyzeMTHFR(variant) {
    const riskMap = {
      'C677T homozygous': { risk: 0.70, description: '70% reduced enzyme activity' },
      'C677T heterozygous': { risk: 0.35, description: '35% reduced enzyme activity' },
      'A1298C homozygous': { risk: 0.50, description: '50% reduced enzyme activity' },
      'A1298C heterozygous': { risk: 0.25, description: '25% reduced enzyme activity' },
      'compound heterozygous': { risk: 0.55, description: '55% reduced enzyme activity' },
      'wild type': { risk: 0.05, description: 'Normal enzyme activity' }
    };
    const result = riskMap[variant] || { risk: 0.10, description: 'Unknown variant' };
    return {
      gene: 'MTHFR',
      variant: variant,
      risk: result.risk,
      condition: 'Cardiovascular/Methylation disorders',
      description: result.description
    };
  }
  
  getCRISPRProtocols(condition) {
    const protocols = this.geneTherapyProtocols.filter(p =>
      p.target.toLowerCase().includes(condition.toLowerCase()) ||
      p.description.toLowerCase().includes(condition.toLowerCase())
    );
    return protocols.length > 0 ? protocols : this.geneTherapyProtocols.slice(0, 3);
  }
  
  getStatus() {
    return {
      module: 'ZORTEX',
      protocolsAvailable: this.geneTherapyProtocols.length,
      epigeneticClocks: this.epigeneticMarkers.length,
      status: 'online'
    };
  }
}

module.exports = ZortexEngine;
